Bollard Group’s Standard BioTools LAB Stock Holding History

Bollard Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,975	Closed	-$7K	–	345
2022 Q1	$7K	Hold	1,975	–	–	﹤0.01%	409
2021 Q4	$8K	Hold	1,975	–	–	﹤0.01%	415
2021 Q3	$13K	Hold	1,975	–	–	﹤0.01%	403
2021 Q2	$12K	Hold	1,975	–	–	﹤0.01%	405
2021 Q1	$9K	Hold	1,975	–	–	﹤0.01%	413
2020 Q4	$12K	Hold	1,975	–	–	﹤0.01%	405
2020 Q3	$15K	Sell	1,975 -6,235	-76%	-$43K	﹤0.01%	395
2020 Q2	$33K	Buy	+8,210	New	+$28.6K	﹤0.01%	379

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bollard Group's LAB Position: Q2 2022 in Review

Bollard Group sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 1,975 shares — an estimated $7K sold.

Bollard Group first reported a position in LAB in Q2 2020 and held it in 8 quarters. The position peaked at $33K in Q2 2020. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

Bollard Group reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 1,975 Standard BioTools shares in Q2 2022, an estimated $7K.
Bollard Group first reported a position in Standard BioTools in Q2 2020 and held it in 8 quarters.
Bollard Group's Standard BioTools position peaked at $33K in Q2 2020.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.